Avalyn Pharma Inc. (AVLN)
Compare with another name Open in your desk ↗
Avalyn Pharma Inc. (AVLN) reported revenue of $3 million for Q2 FY2026, the quarter ended 30 June 2026, up 65.7% on the same quarter a year earlier. Net income was -$29 million, and diluted earnings per share $-0.98. The figures are the company's own, from the 10-Q it filed with the SEC on 12 August 2026.
Revenue$3 millionup 65.7%
Net income-$29 million
Diluted EPS$-0.98
QuarterQ2 FY2026ended 30 June 2026
Avalyn Pharma (AVLN) in brief
Avalyn Pharma had 44 million shares outstanding at the latest filed count.
Read more
At 30 June 2026 it carried $15 million of debt and $264 million of cash. At the close of 30 October 2026 the market cap of Avalyn Pharma was $1.1 billion.Ratios
From the filings
ROEn/a
ROCEn/a
Operating marginn/a
Net marginn/a
FCF marginn/a
Interest covern/a
Debt to equity0.04
Cash conversionn/a
Share count, last 12 months-0.0%
Sales CAGR, 3 yearsn/a
Profit CAGR, 3 yearsn/a
EPS, TTMn/a
At the close of 30 October 2026
Price$25.66
Market cap$1.1 billion
Stock P/En/a
Price to book2.86
EV / EBITDAn/a
Dividend yieldn/a
Market cap / salesn/a
52-week high$39.25
52-week low$23.33
Price, 1 yearn/a
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Avalyn Pharma Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.AVLNgreeksoup.ai
Daily prices to 30 October 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.The public record on AVLN
| Filings | 9 in twelve months: 6 current reports (8-K), about 2 results of operations; 1 officer or director change; 1 material agreement; 1 regulation FD disclosure; 1 charter or bylaw amendment, or fiscal year change |
| Planned insider sales | no Form 144 notice in twelve months |
| Options tape | put/call 2.66 by open interest at the 30 October 2026 close; the straddle prices a 23.8% move to 20 November 2026 |
| 13F holders | 93 funds reported a position for the quarter to 30 June 2026; largest FMR LLC |
| Insider trading | 0 sales and 4 purchases on Form 4 in twelve months |
| Congress | 0 House trades disclosed in six months |
| Short interest | 2.4 million shares short, 6.63 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 2 earnings press releases, each linked |
Quarterly results, the last 4 quarters
| Q1 FY2025 | Q2 FY2025 | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|
| Revenue | 1.2 | 1.6 | 1.1 | 2.7 |
| R&D | 15.3 | 17.9 | 22.9 | 24.7 |
| Operating income | -18.7 | -21.8 | -27.9 | -31.3 |
| Operating margin | -1500% | -1338% | -2481% | -1161% |
| Interest expense | 0.0 | 0.0 | 0.1 | 0.3 |
| Net income | -17.5 | -20.2 | -26.9 | -28.9 |
| Net margin | -1402% | -1241% | -2388% | -1073% |
| Diluted EPS | -$2.63 | -$17.63 | -$0.91 | -$0.98 |
| Operating cash flow | -19.3 | -20.7 | -29.9 | -26.1 |
| Capital expenditure | 0.0 | 0.0 | 0.3 | 0.3 |
| Free cash flow | -19.3 | -20.7 | -30.2 | -26.3 |
| Shares outstanding | 1,064m | 44m | 30m | 44m |
| Filing | 10-Q | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Questions
What is Avalyn Pharma's market cap?
The market cap of Avalyn Pharma was $1.1 billion at the close of 30 October 2026.
How much debt does Avalyn Pharma have?
At 30 June 2026 Avalyn Pharma carried $15 million of debt and $264 million of cash.
Peers: Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Eli Lilly & Co. LLY | $1.33 trillion | 45.95 | 68.5% | n/a | 45.5% | 1.23 | 0.4% |
| Johnson & Johnson JNJ | $657.6 billion | 41.39 | 19.7% | n/a | 7.8% | 0.55 | 1.9% |
| AbbVie Inc. ABBV | $521.0 billion | 83.28 | n/a | 26.2% | 10.4% | n/a | 2.3% |
| Merck & Co., Inc. MRK | $368.9 billion | 119.63 | 7.6% | n/a | 4.6% | 1.29 | 2.2% |
| Novartis AG NVS * | $306.8 billion | 22.49 | 30.3% | n/a | 8.4% | 0.62 | 2.5% |
| AstraZeneca PLC AZN * | $289.5 billion | 28.55 | 21.0% | 23.4% | 8.6% | 0.57 | 1.7% |
| Abbott Laboratories ABT | $183.8 billion | 34.38 | 10.6% | 15.8% | 8.1% | 0.64 | 2.3% |
| Novo Nordisk A/S NVO * | $178.6 billion | 11.59 | 52.8% | 41.3% | 6.4% | 0.67 | 4.4% |
| Pfizer Inc. PFE | $173.8 billion | 40.13 | 5.1% | n/a | -0.2% | 0.74 | 5.6% |
| Vertex Pharmaceuticals Inc. VRTX | $141.6 billion | 32.54 | 21.8% | 38.0% | 10.2% | 0.00 | n/a |
| Bristol-Myers Squibb Co. BMY | $127.7 billion | 13.85 | 39.5% | 22.6% | 4.2% | 1.83 | 4.0% |
| Sanofi SNY * | $108.2 billion | 12.44 | 10.9% | n/a | 6.2% | 0.26 | 5.0% |
All 175 in Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Eli Lilly & Co. LLY | $1.33 trillion | 45.95 | 68.5% | n/a | 45.5% | 1.23 | 0.4% |
| Johnson & Johnson JNJ | $657.6 billion | 41.39 | 19.7% | n/a | 7.8% | 0.55 | 1.9% |
| AbbVie Inc. ABBV | $521.0 billion | 83.28 | n/a | 26.2% | 10.4% | n/a | 2.3% |
| Merck & Co., Inc. MRK | $368.9 billion | 119.63 | 7.6% | n/a | 4.6% | 1.29 | 2.2% |
| Novartis AG NVS * | $306.8 billion | 22.49 | 30.3% | n/a | 8.4% | 0.62 | 2.5% |
| AstraZeneca PLC AZN * | $289.5 billion | 28.55 | 21.0% | 23.4% | 8.6% | 0.57 | 1.7% |
| Amgen Inc. AMGN | $252.0 billion | 28.97 | 74.8% | 30.0% | 9.1% | 4.90 | 2.1% |
| Gilead Sciences, Inc. GILD | $212.0 billion | n/a | -29.6% | -7.6% | 6.5% | 2.01 | 1.9% |
| Abbott Laboratories ABT | $183.8 billion | 34.38 | 10.6% | 15.8% | 8.1% | 0.64 | 2.3% |
| Novo Nordisk A/S NVO * | $178.6 billion | 11.59 | 52.8% | 41.3% | 6.4% | 0.67 | 4.4% |
| Pfizer Inc. PFE | $173.8 billion | 40.13 | 5.1% | n/a | -0.2% | 0.74 | 5.6% |
| Vertex Pharmaceuticals Inc. VRTX | $141.6 billion | 32.54 | 21.8% | 38.0% | 10.2% | 0.00 | n/a |
| Bristol-Myers Squibb Co. BMY | $127.7 billion | 13.85 | 39.5% | 22.6% | 4.2% | 1.83 | 4.0% |
| Sanofi SNY * | $108.2 billion | 12.44 | 10.9% | n/a | 6.2% | 0.26 | 5.0% |
| GSK plc GSK * | $99.3 billion | 13.33 | 34.9% | 24.3% | 4.1% | 1.08 | 3.4% |
| Regeneron Pharmaceuticals, Inc. REGN | $98.0 billion | 20.48 | 14.4% | 28.8% | 18.6% | 0.06 | 0.4% |
| Moderna, Inc. MRNA | $88.5 billion | n/a | -46.6% | -149.0% | -27.6% | 0.09 | n/a |
| Takeda Pharmaceutical Company Limited TAK * | $66.1 billion | n/a | -2.1% | 0.1% | -1.7% | 0.66 | 3.1% |
| argenx SE ARGX * | $55.3 billion | 45.62 | 17.6% | n/a | 89.9% | 0.00 | n/a |
| Teva Pharmaceutical Industries Ltd. TEVA | $49.0 billion | 70.15 | 9.1% | 9.3% | 4.1% | 2.14 | n/a |
| IDEXX Laboratories Inc. IDXX | $43.5 billion | 38.78 | 70.7% | 32.0% | 12.8% | 0.60 | n/a |
| Biogen Inc. BIIB | $37.5 billion | 108.40 | 1.8% | 4.3% | 2.3% | 0.41 | n/a |
| Royalty Pharma plc RPRX | $37.4 billion | 35.93 | 8.3% | 59.6% | 10.0% | 0.92 | 1.4% |
| Genmab A/S GMAB * | $36.6 billion | 37.11 | 16.5% | 28.6% | 19.2% | 0.90 | n/a |
| Zoetis Inc. ZTS | $33.0 billion | 13.13 | 83.1% | n/a | 1.5% | 2.87 | 2.5% |
| Roivant Sciences Ltd. ROIV | $26.7 billion | n/a | -6.3% | -7,914.8% | -67.6% | 0.00 | n/a |
| United Therapeutics Corp. UTHR | $25.5 billion | 21.41 | 20.5% | 44.4% | 2.5% | 0.00 | n/a |
| Insmed Inc. INSM | $24.7 billion | n/a | -83.4% | -37.1% | 240.0% | 0.76 | n/a |
| BioNTech SE BNTX * | $22.1 billion | n/a | -5.9% | -49.0% | 4.3% | 0.01 | n/a |
| Alnylam Pharmaceuticals, Inc. ALNY | $22.1 billion | 8.56 | 75.6% | 19.5% | 56.2% | 0.28 | n/a |
| Viatris Inc. VTRS | $21.9 billion | n/a | -2.9% | -0.6% | 4.4% | 0.94 | 2.5% |
| Exelixis, Inc. EXEL | $17.0 billion | 20.77 | 48.3% | 40.2% | 9.1% | 0.00 | n/a |
| Halozyme Therapeutics, Inc. HALO | $14.9 billion | 39.08 | 288.1% | 35.9% | 41.2% | 14.95 | n/a |
| Neurocrine Biosciences Inc. NBIX | $14.9 billion | 21.44 | 19.1% | 23.6% | 34.4% | 0.00 | n/a |
| BridgeBio Pharma, Inc. BBIO | $14.7 billion | n/a | n/a | -38.5% | 167.3% | n/a | n/a |
| Kiniksa Pharmaceuticals International, plc KNSA | $14.5 billion | 70.85 | 15.4% | 13.8% | 58.2% | 0.00 | n/a |
| Jazz Pharmaceuticals plc JAZZ | $14.0 billion | 14.91 | 19.6% | 19.5% | 12.6% | 0.91 | n/a |
| Dr. Reddy’s Laboratories Limited RDY * | $11.8 billion | 26.18 | 11.4% | 15.0% | 3.2% | 0.21 | 0.6% |
| Elanco Animal Health Inc. ELAN | $11.5 billion | n/a | -3.0% | n/a | 12.0% | 0.56 | n/a |
| Bio-Techne Corp. TECH | $11.3 billion | 63.21 | 8.6% | 20.7% | -0.4% | 0.09 | 0.4% |
| Biomarin Pharmaceutical Inc. BMRN | $11.3 billion | 158.22 | 1.2% | 4.4% | 11.2% | 0.66 | n/a |
| Kymera Therapeutics, Inc. KYMR | $10.8 billion | n/a | -21.6% | -396.0% | 133.8% | 0.00 | n/a |
| Repligen Corp. RGEN | $10.0 billion | n/a | -0.6% | 2.3% | 13.8% | 0.27 | n/a |
| Madrigal Pharmaceuticals, Inc. MDGL | $9.9 billion | n/a | -62.1% | -25.1% | 149.0% | 0.65 | n/a |
| Krystal Biotech, Inc. KRYS | $9.8 billion | 41.56 | 17.8% | 44.9% | 22.6% | 0.00 | n/a |
| Twist Bioscience Corp. TWST | $9.6 billion | n/a | -30.7% | -33.6% | 19.2% | 0.03 | n/a |
| Protagonist Therapeutics, Inc. PTGX | $9.4 billion | 140.71 | 9.9% | 20.7% | 34.8% | 0.00 | n/a |
| TG Therapeutics, Inc. TGTX | $9.4 billion | 22.34 | 73.1% | 17.1% | 76.1% | 1.23 | n/a |
| Corcept Therapeutics Inc. CORT | $8.8 billion | 193.11 | 7.8% | 0.8% | 16.0% | 0.00 | n/a |
| Cytokinetics Inc. CYTK | $8.8 billion | n/a | n/a | -1,046.1% | -21.1% | n/a | n/a |
| ImmunityBio, Inc. IBRX | $8.7 billion | n/a | n/a | -151.9% | 192.9% | n/a | n/a |
| Arrowhead Pharmaceuticals, Inc. ARWR | $8.4 billion | n/a | -68.7% | -33.8% | 16.8% | 1.86 | n/a |
| Alkermes plc. ALKS | $7.6 billion | 119.26 | 3.7% | 7.0% | 10.8% | 0.84 | n/a |
| Axsome Therapeutics, Inc. AXSM | $7.6 billion | n/a | -230.1% | -24.0% | 56.9% | 2.26 | n/a |
| Ionis Pharmaceuticals Inc. IONS | $7.2 billion | n/a | -128.5% | -68.0% | -7.4% | 3.01 | n/a |
| Amneal Pharmaceuticals, Inc. AMRX | $6.9 billion | 43.90 | 476.5% | 14.6% | 9.3% | 80.86 | n/a |
| Lantheus Holdings, Inc. LNTH | $6.6 billion | 24.27 | 21.0% | 19.4% | 2.3% | 0.43 | n/a |
| Ligand Pharmaceuticals Inc. LGND | $6.5 billion | 144.15 | 5.4% | 9.5% | 1.0% | 1.17 | n/a |
| Rhythm Pharmaceuticals, Inc. RYTM | $6.4 billion | n/a | -199.4% | -83.6% | 53.5% | 1.03 | n/a |
| CG Oncology, Inc. CGON | $5.7 billion | n/a | -21.8% | -4,056.2% | 1,030.3% | 0.00 | n/a |
| Mirum Pharmaceuticals, Inc. MIRM | $5.5 billion | n/a | n/a | -134.9% | 44.0% | n/a | n/a |
| Scholar Rock Holding Corp. SRRK | $5.3 billion | n/a | n/a | n/a | n/a | 0.77 | n/a |
| Gossamer Bio, Inc. GOSS | $5.1 billion | n/a | n/a | -311.7% | 32.4% | n/a | n/a |
| PTC Therapeutics, Inc. PTCT | $5.0 billion | n/a | n/a | 12.8% | -35.1% | n/a | n/a |
| Crispr Therapeutics AG CRSP | $5.0 billion | n/a | -25.8% | -3,990.0% | -64.8% | 0.34 | n/a |
| Travere Therapeutics, Inc. TVTX | $4.7 billion | n/a | -177.2% | -6.8% | 77.1% | 24.58 | n/a |
| Adaptive Biotechnologies Corp. ADPT | $4.2 billion | n/a | -44.7% | -12.2% | 50.1% | 2.34 | n/a |
| Indivior Pharmaceuticals, Inc. INDV | $4.2 billion | n/a | n/a | 40.6% | 16.4% | n/a | n/a |
| Arcutis Biotherapeutics, Inc. ARQT | $4.0 billion | 152.62 | 12.9% | 7.4% | 76.1% | 0.49 | n/a |
| Liquidia Corp. LQDA | $4.0 billion | 32.87 | 71.0% | 37.4% | 2,233.6% | n/a | n/a |
| Relay Therapeutics, Inc. RLAY | $4.0 billion | n/a | -32.1% | -2,999.7% | 23.9% | 0.00 | n/a |
| Iovance Biotherapeutics, Inc. IOVA | $3.8 billion | n/a | -39.3% | -92.7% | 34.5% | 0.00 | n/a |
| Tango Therapeutics, Inc. TNGX | $3.8 billion | n/a | -12.1% | -253.4% | 121.5% | 0.00 | n/a |
| AbCellera Biologics Inc. ABCL | $3.8 billion | n/a | -18.4% | -340.2% | 101.3% | 0.00 | n/a |
| Organon & Co. OGN | $3.6 billion | 18.21 | 17.9% | n/a | -3.2% | 7.17 | 0.6% |
| Xenon Pharmaceuticals Inc. XENE | $3.6 billion | n/a | -32.9% | n/a | n/a | 0.00 | n/a |
| Acadia Pharmaceuticals Inc. ACAD | $3.5 billion | 9.27 | 29.1% | 7.6% | 11.8% | 0.00 | n/a |
| Viking Therapeutics, Inc. VKTX | $3.5 billion | n/a | -106.6% | n/a | n/a | 0.43 | n/a |
| Tarsus Pharmaceuticals, Inc. TARS | $3.2 billion | n/a | -13.4% | -8.0% | 105.2% | 0.21 | 0.0% |
| Ideaya Biosciences, Inc. IDYA | $3.1 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Bausch Health Companies Inc. BHC | $3.1 billion | n/a | n/a | 11.2% | 10.8% | n/a | n/a |
| Denali Therapeutics Inc. DNLI | $3.0 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| DBV Technologies S.A. DBVT | $3.0 billion | n/a | -139.5% | -5,420.1% | -31.5% | 0.00 | n/a |
| Nurix Therapeutics, Inc. NRIX | $2.9 billion | 11.60 | 30.5% | 41.3% | 738.8% | 0.00 | 0.0% |
| Beam Therapeutics Inc. BEAM | $2.8 billion | n/a | -8.0% | -242.3% | 158.9% | 0.09 | n/a |
| Silence Therapeutics plc SLN | $2.8 billion | n/a | -155.8% | -11,106.8% | -97.7% | 0.00 | n/a |
| Viridian Therapeutics, Inc. VRDN | $2.8 billion | n/a | -58.4% | -569.7% | 23,220.3% | 0.54 | n/a |
| Neogen Corp. NEOG | $2.6 billion | n/a | -2.7% | -0.8% | -0.3% | 0.37 | n/a |
| Adma Biologics, Inc. ADMA | $2.6 billion | 16.31 | 41.4% | 43.8% | 8.0% | 0.48 | n/a |
| Precigen, Inc. PGEN | $2.5 billion | n/a | n/a | n/a | n/a | 2.15 | n/a |
| Supernus Pharmaceuticals, Inc. SUPN | $2.4 billion | n/a | -4.1% | -5.7% | 26.9% | 0.00 | n/a |
| Celldex Therapeutics, Inc. CLDX | $2.4 billion | n/a | -42.1% | -207,534.4% | -97.3% | 0.00 | n/a |
| NewAmsterdam Pharma Co. N.V. NAMS | $2.4 billion | n/a | -41.1% | -3,432.2% | -88.9% | 0.00 | n/a |
| Prestige Consumer Healthcare Inc. PBH | $2.3 billion | 13.75 | 9.0% | 26.3% | -1.4% | 1.05 | n/a |
| Arcus Biosciences, Inc. RCUS | $2.3 billion | n/a | -99.1% | -415.4% | -55.3% | 0.22 | n/a |
| Harmony Biosciences Holdings, Inc. HRMY | $2.3 billion | 12.59 | 18.1% | 24.0% | 24.3% | 0.15 | n/a |
| Aurinia Pharmaceuticals Inc. AUPH | $2.2 billion | 7.27 | 47.8% | 48.6% | 21.0% | 0.00 | n/a |
| Xencor Inc. XNCR | $2.2 billion | n/a | -32.5% | -205.8% | -28.6% | 0.21 | n/a |
| Perrigo Co. plc PRGO | $2.2 billion | n/a | -69.0% | -37.7% | -4.2% | 1.31 | 7.4% |
| Biocryst Pharmaceuticals Inc. BCRX | $2.2 billion | n/a | n/a | -33.3% | 68.7% | n/a | n/a |
| Recursion Pharmaceuticals, Inc. RXRX | $2.1 billion | n/a | -56.7% | -991.7% | -15.1% | 0.02 | n/a |
| Immunome Inc. IMNM | $2.1 billion | n/a | -48.4% | n/a | n/a | 0.00 | n/a |
| Vericel Corp. VCEL | $2.1 billion | 85.63 | 6.5% | 6.0% | 23.0% | 0.00 | n/a |
| Zymeworks Inc. ZYME | $2.0 billion | n/a | -186.6% | -419.0% | -69.8% | 0.00 | n/a |
| Schrodinger, Inc. SDGR | $2.0 billion | n/a | -16.5% | -59.2% | 8.9% | 0.00 | n/a |
| Septerna, Inc. SEPN | $2.0 billion | n/a | -6.3% | -44.0% | 13,520.1% | 0.00 | n/a |
| Trulieve Cannabis Corp. TRLV | $2.0 billion | n/a | -61.8% | -24.3% | -3.9% | 0.38 | n/a |
| Sarepta Therapeutics, Inc. SRPT | $2.0 billion | n/a | -8.9% | -7.3% | -20.4% | 0.55 | n/a |
| Vir Biotechnology, Inc. VIR | $1.9 billion | n/a | -25.6% | -92.4% | 1,495.9% | 0.00 | n/a |
| Xeris Biopharma Holdings, Inc. XERS | $1.9 billion | n/a | n/a | 10.9% | 36.3% | n/a | n/a |
| Generate Biomedicines, Inc. GENB | $1.9 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Agios Pharmaceuticals, Inc. AGIO | $1.8 billion | n/a | -40.1% | -466.8% | 140.6% | 0.00 | n/a |
| Zenas BioPharma, Inc. ZBIO | $1.8 billion | n/a | n/a | n/a | n/a | 1.20 | n/a |
| Maze Therapeutics, Inc. MAZE | $1.7 billion | n/a | n/a | n/a | n/a | 0.09 | n/a |
| Intellia Therapeutics, Inc. NTLA | $1.7 billion | n/a | -55.0% | -711.7% | 12.6% | 0.00 | n/a |
| uniQure N.V. QURE | $1.7 billion | n/a | -77.8% | -1,071.5% | 30.2% | 0.15 | n/a |
| Novavax Inc. NVAX | $1.7 billion | n/a | n/a | -56.6% | -61.6% | n/a | n/a |
| Nuvation Bio Inc. NUVB | $1.7 billion | n/a | -59.0% | -81.0% | 1,083.6% | 0.98 | n/a |
| Stoke Therapeutics, Inc. STOK | $1.6 billion | n/a | -60.2% | -809.7% | -86.2% | 0.00 | n/a |
| ANI Pharmaceuticals Inc. ANIP | $1.6 billion | 15.32 | 18.1% | 15.4% | 30.9% | 1.02 | n/a |
| UroGen Pharma Ltd. URGN | $1.6 billion | n/a | n/a | -35.3% | 100.3% | n/a | n/a |
| Ultragenyx Pharmaceutical Inc. RARE | $1.6 billion | n/a | n/a | -73.6% | 17.5% | n/a | n/a |
| Phibro Animal Health Corp. PAHC | $1.6 billion | 16.02 | 25.9% | 12.8% | 17.1% | 1.91 | 1.2% |
| Immunocore Holdings plc IMCR | $1.6 billion | n/a | -4.3% | -5.2% | 21.0% | 0.94 | 0.0% |
| Innoviva, Inc. INVA | $1.5 billion | 5.18 | 29.0% | 36.9% | 18.8% | 0.21 | n/a |
| Ocular Therapeutix, Inc. OCUL | $1.5 billion | n/a | -58.0% | -603.0% | -8.1% | 0.14 | n/a |
| Eton Pharmaceuticals, Inc. ETON | $1.5 billion | 133.95 | 27.2% | 15.4% | 81.5% | 0.60 | n/a |
| Pacira BioSciences, Inc. PCRX | $1.4 billion | 103.97 | 2.2% | 2.7% | 5.7% | 0.54 | n/a |
| Taysha Gene Therapies, Inc. TSHA | $1.3 billion | n/a | -38.6% | -2,792.3% | -32.3% | 0.13 | n/a |
| Omeros Corp. OMER | $1.3 billion | n/a | n/a | n/a | n/a | n/a | n/a |
| Opko Health, Inc. OPK | $1.2 billion | n/a | -6.2% | -8.2% | -11.5% | 0.29 | n/a |
| Cronos Group Inc. CRON | $1.2 billion | 16.50 | 6.5% | -1.4% | 37.5% | 0.00 | n/a |
| Syndax Pharmaceuticals Inc. SNDX | $1.2 billion | n/a | -1,462.1% | -77.1% | 222.3% | 16.17 | n/a |
| Rapport Therapeutics, Inc. RAPP | $1.2 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Amphastar Pharmaceuticals, Inc. AMPH | $1.2 billion | 16.41 | 10.2% | 15.7% | 1.0% | 0.79 | n/a |
| Avalyn Pharma Inc. AVLN | $1.1 billion | n/a | n/a | n/a | n/a | 0.04 | n/a |
| Mannkind Corp. MNKD | $1.1 billion | n/a | n/a | 2.3% | 30.5% | n/a | n/a |
| Janux Therapeutics, Inc. JANX | $1.1 billion | n/a | -11.1% | -598.1% | 5,367.0% | 0.00 | n/a |
| Harrow, Inc. HROW | $1.1 billion | n/a | -244.9% | -1.0% | 21.1% | 19.24 | n/a |
| Inhibrx Biosciences, Inc. INBX | $1.1 billion | n/a | n/a | n/a | n/a | n/a | n/a |
| Rigel Pharmaceuticals Inc. RIGL | $960 million | 3.15 | 75.7% | 31.5% | 3.3% | 0.09 | n/a |
| Odyssey Therapeutics, Inc. ODTX | $936 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Monte Rosa Therapeutics, Inc. GLUE | $915 million | n/a | -33.1% | -633.0% | -83.9% | 0.00 | n/a |
| Kura Oncology, Inc. KURA | $914 million | n/a | -612.8% | -411.9% | n/a | 0.20 | n/a |
| QuidelOrtho Corp. QDEL | $904 million | n/a | -59.1% | -30.8% | -2.5% | 1.63 | n/a |
| MeiraGTx Holdings plc MGTX | $893 million | 13.35 | 36.6% | 46.3% | 948.3% | 0.46 | n/a |
| Verastem, Inc. VSTM | $883 million | n/a | n/a | n/a | n/a | 1.48 | n/a |
| Cryoport, Inc. CYRX | $876 million | n/a | n/a | n/a | n/a | 0.38 | n/a |
| Aktis Oncology, Inc. AKTS | $852 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Arbutus Biopharma Corp. ABUS | $834 million | 5.34 | 59.2% | 82.0% | 1,078.8% | 0.00 | n/a |
| Nektar Therapeutics NKTR | $792 million | n/a | -17.4% | -257.8% | -27.2% | 0.00 | n/a |
| Collegium Pharmaceutical, Inc. COLL | $774 million | 19.21 | 15.4% | 19.5% | 14.3% | 3.50 | n/a |
| Ardelyx, Inc. ARDX | $752 million | n/a | -37.4% | -7.9% | 16.8% | 1.69 | n/a |
| Ginkgo Bioworks Holdings, Inc. DNA | $715 million | n/a | -69.2% | -259.9% | -51.5% | 0.00 | n/a |
| Wave Life Sciences, Inc. WVE | $708 million | n/a | -52.4% | -320.9% | n/a | 0.00 | n/a |
| Design Therapeutics, Inc. DSGN | $667 million | n/a | -35.1% | n/a | n/a | 0.00 | n/a |
| Lexicon Pharmaceuticals, Inc. LXRX | $639 million | n/a | -35.0% | -131.4% | -29.0% | 0.29 | n/a |
| Zevra Therapeutics, Inc. ZVRA | $610 million | 10.94 | 26.8% | 60.5% | 119.4% | 0.00 | n/a |
| Myriad Genetics Inc. MYGN | $606 million | n/a | -37.1% | -12.2% | -3.2% | 0.40 | n/a |
| Ironwood Pharmaceuticals Inc. IRWD | $577 million | 4.53 | n/a | 60.1% | 26.2% | n/a | n/a |
| Geron Corp. GERN | $574 million | n/a | n/a | n/a | n/a | 0.55 | n/a |
| Aclaris Therapeutics, Inc. ACRS | $554 million | n/a | -60.8% | -1,050.2% | -51.0% | 0.00 | n/a |
| Puma Biotechnology, Inc. PBYI | $533 million | 20.06 | 19.3% | 13.2% | -2.9% | 0.00 | n/a |
| Arvinas, Inc. ARVN | $513 million | 78.50 | 1.7% | -5.7% | -15.0% | 0.00 | n/a |
| CytomX Therapeutics, Inc. CTMX | $511 million | n/a | -26.4% | -476.2% | -87.0% | 0.00 | n/a |
| Aquestive Therapeutics, Inc. AQST | $490 million | n/a | n/a | -97.5% | 22.6% | n/a | n/a |
| Evolus, Inc. EOLS | $485 million | n/a | n/a | -5.9% | 13.9% | n/a | n/a |
| Gyre Therapeutics, Inc. GYRE | $483 million | n/a | -29.7% | -14.0% | 16.8% | 0.00 | n/a |
| Monopar Therapeutics MNPR | $474 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Phathom Pharmaceuticals, Inc. PHAT | $465 million | n/a | n/a | -9.3% | 86.8% | n/a | n/a |
| CorMedix Inc. CRMD | $442 million | 2.66 | 40.6% | 47.0% | n/a | 0.00 | n/a |
| Crescent Biopharma, Inc. CBIO | $376 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Canopy Growth Corp. CGC | $277 million | n/a | n/a | -54.9% | 6.8% | 0.35 | n/a |
| Atrium Therapeutics, Inc. RNA | $142 million | n/a | n/a | n/a | n/a | n/a | n/a |
| Korsana Biosciences, Inc. KRSA | $128 million | n/a | -131.8% | -359.2% | -12.6% | 0.00 | n/a |
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.